RE:Potential Treatments For Cancer SufferersI usually skip all these sponsored posts. But I am accostumed now to quickly look if there is something interesting to me in a post, and this one caught my attention because I quickly detected the word Actinium in it. I talked about Actinium 225 recently here. It is another radioisotope, but emitting alpha radiations, which is shorter and much more powerful radiations, compared to the beta radiations emitted by Lutetium177. It is now developped for use with dotatate, instead of Lu177. And early clinical trials are testing it with antibodies in ADCs like the company behind this sponsored post.
The interest here is that, in theory, Actinium 225 could be used with TH19P01 and the DOTA linker. Actinium 225 is a very potent cell killer, its radiations are strong enough to break both strands of DNA making it impossible to repair by enzymes. It also works on any kind of cancer because it bypasses any resistance mechanism. I know it is still early, but if the combo TH19P01/Sortilin is as good as advertised by Thera to enter cells expressing it, adding Actinium 225 to it would make it a very lethal weapon against cancer cells. The nice thing is that other companies are already doing the groundwork on it. But if Thera has the best peptide-receptor combo to create an effective PDC against cancer cells, Actinium 225 could be the perfect complement.
https://www.prnewswire.com/news-releases/actinium-to-highlight-expansion-of-targeted-conditioning-portfolio-at-aacr-with-next-generation-actinium-225-based-cd45-targeting-arc-301245337.html
Aristeasa11 wrote: Sponsored Post:
Moreover, these other divisions’ intellectual property portfolio boasts almost 140 patents, and their clinical experience also encompasses around 500 patients treated with Actinium’s ARCs and through their clinical trials. In addition, these other industries are led by some of the brightest medical and research minds in the world. Check disclaimer on profile and landing page.